LifeMD (LFMD) AI Stock Analysis

• Market Cap: $275.02M
• Dividend Yield: N/A
• Average Volume (3M): 946.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 37.74%
• EPS Growth: 69.79%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.06
• Shares Outstanding: 47,417,393
• 10 Day Avg. Volume: 692,951
• 30 Day Avg. Volume: 945,995
• PEG Ratio: 0.44
• Price to Book (P/B): -37.17
• Price to Sales (P/S): 0.96
• P/FCF Ratio: 34.12
• Enterprise Value/Market Cap: 2.16
• Enterprise Value/Revenue: 2.55
• Enterprise Value/Gross Profit: 2.76
• Enterprise Value/Ebitda: 69.31
• 1Y Price Target: $14.00
• Price Target Upside: 128.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 45 Neutral
• Price Target: $5.50 ▼(-10.13% Downside)

LifeMD's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue growth and high leverage. Technical analysis indicates bearish momentum, further weighing down the score. While the earnings call provided some positive insights, such as telehealth growth and strategic initiatives, these are offset by operational challenges and revised guidance. The valuation remains unattractive due to ongoing losses.

Positive Factors

Telehealth Revenue Growth

The significant growth in telehealth revenue and EBITDA indicates strong demand and operational efficiency, supporting long-term business expansion.

AI Integration

AI integration enhances operational efficiency and patient care, positioning LifeMD for sustainable growth in the evolving telehealth market.

Debt-Free Status

Being debt-free improves financial stability and flexibility, allowing LifeMD to reinvest in growth opportunities without the burden of interest expenses.

Negative Factors

Declining Revenue Growth

The sharp decline in revenue growth poses a risk to LifeMD's market position and ability to sustain long-term operations without strategic adjustments.

High Leverage

High leverage limits financial flexibility and increases risk, potentially impacting LifeMD's ability to invest in growth and weather economic downturns.

Revised Financial Guidance

The downward revision in financial guidance reflects operational challenges and market uncertainties, impacting investor confidence and future growth prospects.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

How the Company Makes Money

LifeMD generates revenue through multiple streams, primarily by charging patients for telehealth consultations and the sale of prescription medications. The company operates on a direct-to-consumer model, allowing it to reach a broad audience seeking convenient healthcare services. Significant revenue comes from subscription programs where patients pay for ongoing access to healthcare services and personalized treatment plans. Additionally, LifeMD may benefit from strategic partnerships with pharmacies and healthcare providers, which can enhance its service offerings and expand its customer base, further contributing to its earnings.

LifeMD Financial Statement Overview

Summary

LifeMD faces significant challenges with declining revenue growth and negative profitability margins. The balance sheet is heavily leveraged, posing financial risks. However, the company has shown strong free cash flow growth, which is a positive indicator of cash generation capability. Overall, while there are strengths in cash flow, the financial health of the company is concerning due to high leverage and negative profitability.

Income Statement

LifeMD has shown a significant decline in revenue growth with a TTM (Trailing-Twelve-Months) revenue growth rate of -95%. The gross profit margin remains strong at 91.97%, indicating efficient cost management. However, the net profit margin is negative at -5.21%, reflecting ongoing profitability challenges. EBIT and EBITDA margins are also weak, suggesting operational inefficiencies.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of -10.78, indicating significant leverage and potential financial risk. Return on equity is positive at 2.33%, but this is due to negative equity, which is a concerning sign. The equity ratio is not favorable, suggesting a reliance on debt financing.

Cash Flow

LifeMD's cash flow statement shows a remarkable free cash flow growth of 318.98% in the TTM period, indicating improved cash generation. The operating cash flow to net income ratio is 0.25, and the free cash flow to net income ratio is 0.21, reflecting moderate cash flow efficiency despite negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	232.45M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	215.05M	242.40M	133.65M	100.37M	74.88M	28.39M
EBITDA	8.55M	-6.65M	-8.21M	-39.61M	-53.95M	-57.48M
Net Income	-6.70M	-18.88M	-20.60M	-45.02M	-61.32M	-60.52M
Balance Sheet
Total Assets	73.56M	72.46M	58.48M	25.67M	49.92M	13.05M
Cash, Cash Equivalents and Short-Term Investments	36.23M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	22.05M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	73.18M	76.51M	52.91M	32.97M	24.10M	13.88M
Stockholders Equity	-1.78M	-5.49M	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	13.27M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	19.48M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.78M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-6.17M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 6.12 is below the 20-day moving average (MA) of 6.33, below the 50-day MA of 6.30, and below the 200-day MA of 7.77, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 34.87 is Neutral, neither overbought nor oversold. The STOCH value of 23.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PETS	―	$52.96M	―	―	―	-19.25%	14.47%
LFMD	―	$275.02M	―	―	―	37.74%	69.79%
YI	―	$37.95M	-3.69	―	―	-3.54%	77.98%

LifeMD Corporate Events

LifeMD Earnings Call: Mixed Sentiments and Strategic Moves

In the latest earnings call, LifeMD, Inc. presented a mixed sentiment with notable achievements and some challenges. The company reported strong performances in its telehealth and WorkSimpli segments, alongside strategic debt repayment and new program launches in behavioral and women’s health. However, these positives were counterbalanced by higher refund rates, challenges in the RexMD segment, and a downward revision in financial guidance.

LifeMD, Inc. Reports Strong Q2 2025 Growth

LifeMD, Inc., a prominent player in the virtual primary care sector, offers telemedicine services, laboratory and pharmacy access, and specialized treatments across various health conditions. The company is recognized for its vertically integrated digital care platform and extensive reach across the United States.

LifeMD Appoints Shayna Webb Dray as COO

On July 31, 2025, LifeMD announced the appointment of Shayna Webb Dray as Chief Operating Officer, effective March 27, 2025. With over 15 years of experience in operations and supply chain management, Webb Dray has been instrumental in LifeMD’s growth, previously serving as Senior Vice President of Operations. Her leadership is expected to support LifeMD’s expansion into new verticals and enhance patient care quality. Additionally, LifeMD expanded the roles of two other executives, promoting Jessica Friedeman to Chief Marketing and Product Officer and Jacob Ellison to Chief Analytics Officer, reflecting the company’s focus on internal talent to drive innovation and growth.

The most recent analyst rating on (LFMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.